These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
302 related articles for article (PubMed ID: 3986938)
21. [Comparative bactericidal activity of beta-lactam-aminoglycoside combinations against Pseudomonas aeruginosa]. Cluzel M; Chanal M; Sirot J; Cluzel R Nouv Presse Med; 1982 Nov; 11(46):3400-4. PubMed ID: 6818523 [TBL] [Abstract][Full Text] [Related]
22. Chemotherapy against Pseudomonas aeruginosa in cystic fibrosis. A study of carbenicillin, azlocillin or piperacillin in combination with tobramycin. Møller NE; Eriksen KR; Feddersen C; Flensborg EW; Høiby N; Norn S; Rosendal K; Schiøtz PO; Skov PS Eur J Respir Dis; 1982 Mar; 63(2):130-9. PubMed ID: 6461561 [TBL] [Abstract][Full Text] [Related]
23. Novel antibiotic combinations against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter species. Rahal JJ Clin Infect Dis; 2006 Sep; 43 Suppl 2():S95-9. PubMed ID: 16894522 [TBL] [Abstract][Full Text] [Related]
24. Cefsulodin and ceftazidime, two antipseudomonal cephalosporins. Smith BR Clin Pharm; 1984; 3(4):373-85. PubMed ID: 6380902 [TBL] [Abstract][Full Text] [Related]
25. Risk of emergence of Pseudomonas aeruginosa resistance to beta-lactam antibiotics in intensive care units. Georges B; Conil JM; Dubouix A; Archambaud M; Bonnet E; Saivin S; Lauwers-Cancès V; Cristini C; Cougot P; Decun JF; Mathe O; Chabanon G; Marty N; Seguin T; Houin G Crit Care Med; 2006 Jun; 34(6):1636-41. PubMed ID: 16557152 [TBL] [Abstract][Full Text] [Related]
26. [Pseudomonas aeruginosa: acquired in vitro resistance to beta-lactams]. Thabaut A; Meyran M Pathol Biol (Paris); 1983 May; 31(5):387-91. PubMed ID: 6413939 [TBL] [Abstract][Full Text] [Related]
27. Comparison of the in vitro activity of new beta-lactams and aminoglycosides against clinical isolates of Pseudomonas aeruginosa. Patzer J; Gieburowska R; Dzierzanowska D Zentralbl Bakteriol Mikrobiol Hyg A Med Mikrobiol Infekt Parasitol; 1982 Oct; 253(1):110-20. PubMed ID: 6817544 [TBL] [Abstract][Full Text] [Related]
28. Beta-lactam and aminoglycoside resistance rates and mechanisms among Pseudomonas aeruginosa in French general practice (community and private healthcare centres). Dubois V; Arpin C; Dupart V; Scavelli A; Coulange L; André C; Fischer I; Grobost F; Brochet JP; Lagrange I; Dutilh B; Jullin J; Noury P; Larribet G; Quentin C J Antimicrob Chemother; 2008 Aug; 62(2):316-23. PubMed ID: 18467306 [TBL] [Abstract][Full Text] [Related]
29. Experience with cefsulodin therapy for lower respiratory tract infections caused by Pseudomonas aeruginosa in adults without cystic fibrosis or granulocytopenia. Nichols L; Gudmundsson S; Maki DG Rev Infect Dis; 1984; 6 Suppl 3():S711-20. PubMed ID: 6443772 [TBL] [Abstract][Full Text] [Related]
30. Development of resistance during antimicrobial therapy: a review of antibiotic classes and patient characteristics in 173 studies. Fish DN; Piscitelli SC; Danziger LH Pharmacotherapy; 1995; 15(3):279-91. PubMed ID: 7667163 [TBL] [Abstract][Full Text] [Related]
31. Novel approach to the eradication of Pseudomonas aeruginosa in an infant with CF after outpatient treatment failure. Hayes D; Kanga JF; Anstead MI; Kuhn RJ Pediatr Pulmonol; 2008 May; 43(5):511-3. PubMed ID: 18383117 [TBL] [Abstract][Full Text] [Related]
32. [Antibiotic treatment of cystic fibrosis]. de Montalembert M; Berche P; Lenoir G Ann Pediatr (Paris); 1991 Oct; 38(8):523-8. PubMed ID: 1746849 [TBL] [Abstract][Full Text] [Related]
33. The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way? Banerjee D; Stableforth D Drugs; 2000 Nov; 60(5):1053-64. PubMed ID: 11129122 [TBL] [Abstract][Full Text] [Related]
34. [Treatment of severe infections: should one always administer an aminoglycoside?]. Cometta A; Baumgartner JD Schweiz Med Wochenschr Suppl; 1996; 76():28S-33S. PubMed ID: 8677416 [TBL] [Abstract][Full Text] [Related]
35. Correlation between activity of beta-lactam agents in vitro and bacteriological outcome in acute pulmonary exacerbations of cystic fibrosis. Gaillard JL; Cahen P; Delacourt C; Silly C; Le Bourgeois M; Coustère C; de Blic J; Lenoir G; Scheinmann P Eur J Clin Microbiol Infect Dis; 1995 Apr; 14(4):291-6. PubMed ID: 7649191 [TBL] [Abstract][Full Text] [Related]
36. Cefsulodin for the treatment of Pseudomonas infections--a study comparing cefsulodin and ticarcillin. van der Meer JW; Matze-van der Lans A; Mattie H Neth J Med; 1989 Jun; 34(5-6):233-42. PubMed ID: 2671757 [TBL] [Abstract][Full Text] [Related]
37. Azlocillin in cystic fibrosis. Malmborg AS; Alfredsson H; Strandvik B Isr J Med Sci; 1983 Nov; 19(11):1001-3. PubMed ID: 6662681 [TBL] [Abstract][Full Text] [Related]
38. Value of inhaled antibiotics in cystic fibrosis patients. Wunderlich P; Paul KD; Wehner J Acta Univ Carol Med (Praha); 1990; 36(1-4):34-6. PubMed ID: 2130713 [TBL] [Abstract][Full Text] [Related]
39. In nosocomial pneumonia, optimizing antibiotics other than aminoglycosides is a more important determinant of successful clinical outcome, and a better means of avoiding resistance. Schentag JJ; Birmingham MC; Paladino JA; Carr JR; Hyatt JM; Forrest A; Zimmer GS; Adelman MH; Cumbo TJ Semin Respir Infect; 1997 Dec; 12(4):278-93. PubMed ID: 9436955 [TBL] [Abstract][Full Text] [Related]
40. [Sensitivity of Pseudomonas aeruginosa to beta-lactam antibiotics and effects of beta-lactamases]. Avril JL; Cayla AM; Guist'hau O; Moillo-Batt A Pathol Biol (Paris); 1983 Jun; 31(6):471-5. PubMed ID: 6410345 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]